Drug Trial Radar · NCT00146627
Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis
Last checked: Nov 20, 2026Latest source record: Sep 29, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
280
Planned (sponsor's estimate)
Start
Not stated
Primary completion
Jun 2008
Study completion Jun 2008
Sponsor
- Lead sponsor
- Drugs for Neglected DiseasesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Medecins Sans Frontieres, Netherlands; PNLTHA-DRC;; PNLTHA-RoC; Epicentre; Swiss Tropical & Public Health Institute; World Health Organization
- First posted
- Sep 7, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 15 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the therapeutic combination of I.V. eflornithine + oral nifurtimox to the standard IV eflornithine regimen in terms of therapeutic efficacy and clinical safety, in patients suffering from Trypanosoma brucei gambiense (Tbg) human African trypanosomiasis (HAT) in the meningoencephalitic phase.
Conditions
- Trypanosomiasis, African
Interventions
EflornithineDrug
NifurtimoxDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
MSF-Belgium; PNLTHA, Epicentre
Isangi, Democratic Republic of the Congo
PNLTHA, STI, Epicentre
Katanda, Democratic Republic of the Congo
PNLTHA, STI, Epicentre
Mbuyi Maji, Democratic Republic of the Congo
MSF-Holland
Nkayi, RoC, Republic of the Congo
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.